TABLE 4

Summary of preclinical efficacy of group III mGlu receptor allosteric modulators in schizophrenia-related deficits

ReceptorTypeCompoundPositive Symptom ModelsNegative Symptoms ModelsCognitive ModelsReferences
mGlu4PAMADX88178Reduced NMDAR-HL; reduced DOI-induced head twitchesReduced immobility in FSTKalinichev et al., 2014
Lu AF21934Reduced NMDAR-HL and AHL;a reduced DOI-induced head twitchesaReduced MK-801-induced deficits in social interactionaRescued MK-801-induced deficits in the delayed spatial alternation task;a reduced MK-801-induced deficits in NOR(See footnotes.)
Lu AF32615Reduced NMDAR-HL and AHL; reduced DOI-induced head twitchesReversed MK-801-induced deficits in social interactionReversed MK-801-induced deficits in the delayed spatial alternation taskSławińska et al., 2013
mGlu7Ago-PAMAMN082No effect on AHL; exacerbated NMDAR-HL;b exacerbated DOI-induced head twitchesc(See footnotes.)
NAMMMPIP ADX71743Inhibited MK-801-induced hyperactivity and reversed deficits in PPIReversed MK-801-induced deficits in NOR and spatial delayed alternationCieślik et al., 2018
  • AHL, amphetamine-induced hyperlocomotion; HL, hyperlocomotion; NOR, novel object recognition.

  • aSławińska et al., 2013.

  • bMitsukawa et al., 2005.

  • cWierońska et al., 2012a.